Abrocitinib, marketed as Cibinqo, is a Janus kinase 1 (JAK1) inhibitor used to treat moderate to severe atopic dermatitis [1]. The patent landscape for abrocitinib involves several layers, including patents on the compound itself, its manufacturing processes, and its therapeutic uses [2].
When does abrocitinib's patent expire?
The expiration date for patents related to abrocitinib depends on the specific patent and its jurisdiction [2]. Drug patents typically have a lifespan of 20 years from the filing date, but this can be extended through mechanisms like Patent Term Extension (PTE) in the United States or Supplementary Protection Certificates (SPCs) in Europe, often to compensate for time lost during regulatory review [3]. Information on specific patent expiry dates for abrocitinib can be found on specialized databases like DrugPatentWatch.com [2].
What types of patents protect abrocitinib?
Abrocitinib is protected by multiple patents. These often cover the active pharmaceutical ingredient (API) itself, methods of manufacturing the API, specific polymorphic forms of the API, pharmaceutical formulations, and methods of treating diseases with the drug [2][4]. For example, patents may claim the chemical synthesis routes used to produce abrocitinib or its specific crystalline structures that impact stability and bioavailability [4].
How are abrocitinib patents challenged?
Patents covering abrocitinib can be challenged through various legal and regulatory avenues. Competitors seeking to market generic versions of the drug may file Paragraph IV certifications in the U.S., challenging the validity or enforceability of existing patents. This can lead to patent litigation. In other regions, administrative review processes or invalidity actions can be initiated [2]. These challenges often center on whether the claimed invention was novel, obvious, or adequately described in the patent application [5].
Can generic versions of abrocitinib be developed?
The development of generic versions of abrocitinib is contingent on the expiration or successful legal invalidation of the relevant patents that grant market exclusivity to the innovator company, Pfizer [1][2]. Once these patent barriers are removed, generic manufacturers can seek regulatory approval to market their versions, provided they demonstrate bioequivalence to the brand-name drug [3].
What is the regulatory pathway for abrocitinib?
Abrocitinib has received marketing authorization from regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1]. The approval process involves rigorous review of preclinical and clinical trial data demonstrating the drug's safety and efficacy for its intended use. This regulatory approval period is often factored into patent term restorations [3].
What are the clinical uses and patient concerns for abrocitinib?
Abrocitinib is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients [1]. Patient concerns often revolve around the drug's effectiveness, potential side effects, and long-term safety profile [6]. Like other JAK inhibitors, monitoring for potential risks such as serious infections, thrombosis, and certain malignancies is a key aspect of its post-market surveillance [1][7].
What are the safety considerations for JAK inhibitors like abrocitinib?
JAK inhibitors, including abrocitinib, carry a boxed warning in the U.S. regarding increased risks of mortality, major cardiovascular events, and thrombosis [1][7]. These risks have been identified through clinical trials and post-marketing surveillance. Patients and healthcare providers must carefully weigh these potential risks against the benefits of treatment [7].
Who are the main competitors in the JAK inhibitor market?
The market for JAK inhibitors is competitive, with several other drugs targeting similar pathways for autoimmune and inflammatory conditions [8]. Key competitors include other JAK inhibitors approved for atopic dermatitis or related conditions, such as upadacitinib (Rinvoq) and baricitinib (Olumiant) [9][10]. These drugs may have different patent exclusivity periods and therapeutic profiles [2].
Sources:
[1] https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-cibinqo-abrocitinib-daily-oral-treatment-moderate
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/drugs/patent-certification-and-pharmaceutical-competition/patent-term-restoration
[4] https://patents.google.com/
[5] https://www.uspto.gov/patents/basics/what-patent
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945112/
[7] https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-serious-infections-blood-clots-stomach-cancer-heart-attack-and-stroke
[8] https://www.bmj.com/content/376/bmj-2021-068177
[9] https://www.fda.gov/drugs/drug-approvals/rinvoq-upadacitinib
[10] https://www.fda.gov/drugs/drug-approvals/olumiant-baricitinib